Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...

Manufacturers improved purification techniques, introduced standardized strengths and developed new long-acting insulins ... Zinc & Iletin (Insulin, Lilly), 10cc, List No. M-140 National Museum of ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

In the meantime, Novo Nordisk has responded to the threat from the cut-price fast and long-acting insulins with newer insulins that aim to improve on the performance of the established rivals.

said the company's decision to discontinue Levemir, a long-acting insulin, "failed to take into ... was announced just before Novo Nordisk's 65% list price cut of Levemir took effect on January ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...